WO1990009797A1 - Orally administerable calcium supplement for cattle - Google Patents

Orally administerable calcium supplement for cattle Download PDF

Info

Publication number
WO1990009797A1
WO1990009797A1 PCT/DK1990/000055 DK9000055W WO9009797A1 WO 1990009797 A1 WO1990009797 A1 WO 1990009797A1 DK 9000055 W DK9000055 W DK 9000055W WO 9009797 A1 WO9009797 A1 WO 9009797A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
oil
calcium
composition according
phase
Prior art date
Application number
PCT/DK1990/000055
Other languages
French (fr)
Inventor
Gunnar Kjems
Original Assignee
Gunnar Kjems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099089&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1990009797(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gunnar Kjems filed Critical Gunnar Kjems
Priority to AT90904254T priority Critical patent/ATE83664T1/en
Priority to US07/761,364 priority patent/US5393535A/en
Priority to DE9090904254T priority patent/DE69000663T2/en
Publication of WO1990009797A1 publication Critical patent/WO1990009797A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present invention concerns an orally administerable composition for prevention and treatment of calcium de ⁇ ficiency in cattle, e.g. milk fever, said composition con ⁇ taining as active component a readily absorbable calcium compound.
  • Milk fever is a disease which is particularly caused by a strong decline in the Ca content of the blood in the period immediately up to calving and at the beginning of lactation.
  • the predominant part (about 75%) of the inci ⁇ dences occur during the first 24 hours after calving (M. Dantzer, Dansk Vet. Tidsskr. 1987, 70, 4 15/2, p. 148-
  • the disease is normally treated by intravenous in ⁇ jection of calcium, in particular in the form of calcium borongluconate.
  • Cows which have once suffered from milk fever are parti ⁇ cularly predisposed to acquire the disease again at the time of subsequent parturitions, and the disease occurs frequently in older cows (Dantzer, op. cit.).
  • a preferred method, cf. G. Jonsson op. cit., to prevent milk fever is short term oral administration of readily absorbed calcium salts.
  • the rapid absorption of calcium from a calcium chloride solution has been demonstrated by i.a. Hallgren, Wien. Tierartztl. Mschr. 5_2 (1965), p. 359- 369, whose preliminary experiments showed a good preven ⁇ tive effect.
  • the bitter taste and locally irri ⁇ tating effect of calcium chloride entail that the cows are extremely unwilling to take the solutions, which involves a risk of aspiration and consequent aspiration pneumonia, etching of lung and dead.
  • a stomach probe was therefore used in Hallgren's experiments so that the solution was administered directly in the stomach.
  • a commercially available product contains CaCl ⁇ and MgO in a viscous solution. This product is not taken willingly by the cows and therefore involves a risk of aspiration.
  • the aspiration problem can be reduced additionally by mix ⁇ ing calcium chloride in gels on the basis of water and in- ert cellulose derivatives, such as hydroxyethylcellulose or ethylcellulose.
  • the US Patent Specification 3 461 203 reports experiments where water-free CaCl 2 in amounts of 232, 115 and 100 were mixed with 9-10 g of hydroxyethyl ⁇ cellulose and water up to 450-400 ml. These gels were ad- ministered daily for 5-10 days, of which two days were post partum. The milk fever incidence was reduced by from about 50% in the control groups to about 10% in the treated groups.
  • the drawbacks of this method are the difficulty in predicting calving with sufficient accuracy, just as the farmers re ⁇ gard the method as very laborious, in particular because of the resistance of the cows.
  • Dantzer also examined the effect of the so-called calving lime which consists of 95% CaHPO ⁇ and 5% MgO as well as 96000 vitamin D 3 per dose.
  • the invention is based on the surprising finding that the troubles can be remedied by the use of calcium compounds, in particular calcium chloride, if the calcium compound is suspended or emulsified in an oil phase.
  • the invention concerns an orally admini ⁇ sterable composition for prevention or treatment of milk fever in cattle, said composition containing as active ingredient a readily absorbable calcim compound, the com- position being characterized in that the calcium compound is suspended or emulsified in an oil phase.
  • the total calcium content in serum consists of a diffusable portion (about 55%) in equilibrium with a protein bonded portion (about 45%).
  • the diffusable portion which is the readily useful portion, consists of about 45% free calcium ions and about 10% complex bonded calcium. This equilibrium is pH dependent and is shifted towards free calcium ions with a declining pH.
  • the constituent calcium compound Since only the ionized calcium (Ca ) is absorbed from the intestine of the cow, the constituent calcium compound must therefore be water soluble, and to make the pH of the serum go in an acidic direction salts having an acidosing effect, such as calcium chloride, are preferred.
  • oils are vegetable oils, such as soybean oil, rapeseed oil, olive oil, groundnut oil, apricot kernel oil, grapeseed oil, almond oil, linseed oil, peach kernel oil, palm oil, coconut oil, castor oil, sunflower oil and corn oil. Also animal oils, such as fish oils, can be used.
  • composition of the invention is charac ⁇ terized in that the calcium compound is suspended or emul- sified in an oil phase.
  • the composition may thus comprise 0-80%, in particular 0-70% water phase, and 100-20%, in particu ⁇ lar 100-30% oil phase.
  • the preferred mixing ratio is 40- 70% water phase and 60-30% oil phase.
  • the content of calcium calculated as free Ca in the fi ⁇ nished mixture is 1-25% by weight, preferably 10-20%.
  • the calcium compound is thus dissolved in the aqueous phase in a water-in-oil emulsion.
  • the emulsion con ⁇ tains one or more emulsifiers.
  • Suitable emulsifiers are e.g. oil soluble non-ionic emulsifiers, in particular es ⁇ ters of polyvalent alcohols, preferably glycerol, with fatty acids or polymerized oils.
  • emulsion stabi- lity may be obtained with polyglycerol esters of polyme ⁇ rized soybean oil.
  • the concrete emulsifier selection and emulsifier amount depend i.a. upon the ratio of water phase to oil phase, the type of the oil phase and the amount of dissolved cal ⁇ cium compound.
  • the emulsifier is used in an amount of 0.5-10%, calculated on the finished mixture, in particular 1-4%, preferably 1.5-2.5%.
  • composition of the invention may moreover contain additives such as mineral supplements, e.g. magnesium or selenium, vitamin D and flavouring substances, sweetening agents, antioxidants and preservatives. If desired, thickeners may moreover be added to one or both phases.
  • the calcium compound is dissolved in water together with optional preservatives and thickeners and is heated to about 50°C.
  • This solution is mixed with an about 50°C hot solution of emulsifier and optional antioxidants, sweetening agents and flavouring substances in the oil used with vigorous stirring.
  • the resulting emulsion may be homogenized if desired.
  • the suspension may be produced analogously, however with ⁇ out addition of water.
  • the desirable peroral dose is 50 g of free Ca which is administered in prophylactic treatment 24 hours before ex ⁇ pected calving, immediately after calving as well as 12 and 24 hours later.
  • Peroral treatment is also used as a supplement to intra- veneous calcium treatment and is then dosed with 50 g of Ca 4, 12 and optionally 24 hours after the intraveneous treatment.
  • composition according to the invention may e.g. be com ⁇ posed as follows:
  • a typical composition may consist of:
  • composition of the invention is being tested in a large number of herds.
  • Jess J ⁇ rgensen et al., Dansk Vet. Tidsskrift, 1990, 73, 3 1/2, p. 140 refers to comparitive examinations between CaCl 2 gels with hydroxyethylcellulose as gel former and a composition according to the invention in the form of an emulsion in 380 g of soybean oil. Both compositions con- tained 400 ml, 49% aqueous CaCl 2 , H 2 0. It was conluded that the gel composition in the dose used can cause pronounced clinical and pathological side ef ⁇ fects, in particular by way of lesions of the stomach wall while the composition of the invention only involved rela- tively mild clinical symptoms and superficial or no patho ⁇ logical lesions.

Abstract

The orally administerable composition for prevention or treatment of calcium deficiency, in particular milk fever, in cattle contains a readily absorbable calcium compound, preferably calcium chloride, suspended or emulsified in an oil phase, preferably soybean oil. The emulsion contains a water soluble, preferably non-ionic emulsifier, in particular a polyglycerol ester of polymerized oils. The composition consists of 0-80 % by weight of water phase and 100-20 % by weight of oil phase, preferably 40-70 % by weight of water phase and 60-30 % by weight of oil phase. The calcium content calculated as free Ca++ in the finished mixture is 1-25 % by weight, preferably 10-20 % by weight, and the emulsifier content is 0.5-10 % by weight, preferably 1-4 % by weight, in particular 1.5-2.5 % by weight, calculated on the total mixture. The composition is taken willingly by cows without any risk of aspiration.

Description

Orally administerable calcium supplement for cattle
The present invention concerns an orally administerable composition for prevention and treatment of calcium de¬ ficiency in cattle, e.g. milk fever, said composition con¬ taining as active component a readily absorbable calcium compound.
Milk fever is a disease which is particularly caused by a strong decline in the Ca content of the blood in the period immediately up to calving and at the beginning of lactation. The predominant part (about 75%) of the inci¬ dences occur during the first 24 hours after calving (M. Dantzer, Dansk Vet. Tidsskr. 1987, 70, 4 15/2, p. 148-
154). The disease is normally treated by intravenous in¬ jection of calcium, in particular in the form of calcium borongluconate.
In Denmark 4-6% of first-time parturitions are complicated by milk fever, but in Sweden the figure is even higher, about 8%, cf. G. Jonsson, The Veterinary Record, (1978), 102, 165-169. However, there are considerably variations between the herds, depending upon race, yield, average age and feed composition.
Cows which have once suffered from milk fever are parti¬ cularly predisposed to acquire the disease again at the time of subsequent parturitions, and the disease occurs frequently in older cows (Dantzer, op. cit.).
A preferred method, cf. G. Jonsson op. cit., to prevent milk fever is short term oral administration of readily absorbed calcium salts. The rapid absorption of calcium from a calcium chloride solution has been demonstrated by i.a. Hallgren, Wien. Tierartztl. Mschr. 5_2 (1965), p. 359- 369, whose preliminary experiments showed a good preven¬ tive effect. However, the bitter taste and locally irri¬ tating effect of calcium chloride entail that the cows are extremely unwilling to take the solutions, which involves a risk of aspiration and consequent aspiration pneumonia, etching of lung and dead. A stomach probe was therefore used in Hallgren's experiments so that the solution was administered directly in the stomach.
I goes without saying that this method is not feasible as a general prevention without veterinary assistance.
To remedy these drawbacks, CaCl2 in the form of viscous liquids have been used for several years. Since cows can- not spit, they generally have no alternative but to swal¬ low liquids which are so viscous that they do not run out of the mouth.
A commercially available product contains CaCl~ and MgO in a viscous solution. This product is not taken willingly by the cows and therefore involves a risk of aspiration.
The aspiration problem can be reduced additionally by mix¬ ing calcium chloride in gels on the basis of water and in- ert cellulose derivatives, such as hydroxyethylcellulose or ethylcellulose. The US Patent Specification 3 461 203 reports experiments where water-free CaCl2 in amounts of 232, 115 and 100 were mixed with 9-10 g of hydroxyethyl¬ cellulose and water up to 450-400 ml. These gels were ad- ministered daily for 5-10 days, of which two days were post partum. The milk fever incidence was reduced by from about 50% in the control groups to about 10% in the treated groups. According to G. Jonsson, op. cit., the drawbacks of this method are the difficulty in predicting calving with sufficient accuracy, just as the farmers re¬ gard the method as very laborious, in particular because of the resistance of the cows.
In view of this Jonsson and associates shortened the gel treatment, but still administered 150 g or 100 g of water- free CaCl2 dispersed in hydroxy ethyl cellulose and water up to 450 ml leading to a reduction of the milk fever in¬ cidence from 46 to 23%.
However, Jonsson concluded that even though gel intake is relatively convenient, voluntary intake of CaCl2 would be better. Jonsson therefore disguised the bitter taste of CaCl2 in a feed supplement, but obtained no preventive ef¬ fect on milk fever, which he attributes to the fact that almost all cows cease eating on the day of calving or the day before.
Dantzer, op. cit., moreover states that CaCl2 gels are acid and taken only unwillingly by the cows.
As mentioned more fully below, Jess Jørgensen et al.,
Dansk Vet. Tidsskr. 1990, 73, 3 1/2, p. 140 reports exa¬ minations which show that CaCl2 gels on the basis of hy- droxyethylcellulose can have an etching effect on the stomach wall in cows.
Dantzer also examined the effect of the so-called calving lime which consists of 95% CaHPO^ and 5% MgO as well as 96000 vitamin D3 per dose.
Dantzer reports that the product is willingly taken per- orally by the cows. MgO is added because many cows suffer from hypomagnesemaemia, which makes them predisposed to milk fever. Dantzer's conclusion to the admittedly limited test material is that calving lime is less effective than CaCl2 gel. The reason is presumably the limited solubility of CaHPO. and the consequent limited calcium absorption. Thus, there is still a need for a calcium based composi¬ tion which effectively prevents milk fever, which is taken willingly by the cows, and which is not vitiated by any risk of aspiration upon oral intake.
The invention is based on the surprising finding that the troubles can be remedied by the use of calcium compounds, in particular calcium chloride, if the calcium compound is suspended or emulsified in an oil phase.
In view of this the invention concerns an orally admini¬ sterable composition for prevention or treatment of milk fever in cattle, said composition containing as active ingredient a readily absorbable calcim compound, the com- position being characterized in that the calcium compound is suspended or emulsified in an oil phase.
As explained by Hallgren and Dantzer, op. cit., the total calcium content in serum consists of a diffusable portion (about 55%) in equilibrium with a protein bonded portion (about 45%). The diffusable portion, which is the readily useful portion, consists of about 45% free calcium ions and about 10% complex bonded calcium. This equilibrium is pH dependent and is shifted towards free calcium ions with a declining pH.
Since only the ionized calcium (Ca ) is absorbed from the intestine of the cow, the constituent calcium compound must therefore be water soluble, and to make the pH of the serum go in an acidic direction salts having an acidosing effect, such as calcium chloride, are preferred.
Also other soluble calcium salts are useful, such as cal¬ cium formate, calcium acetate, calcium propionate, calcium gluconate, calcium borongluconate, calcium lactate, cal¬ cium laevulate, and calcium ascorbate. The oil phase is formed by an edible oil. Preferred oils are vegetable oils, such as soybean oil, rapeseed oil, olive oil, groundnut oil, apricot kernel oil, grapeseed oil, almond oil, linseed oil, peach kernel oil, palm oil, coconut oil, castor oil, sunflower oil and corn oil. Also animal oils, such as fish oils, can be used.
As mentioned, the composition of the invention is charac¬ terized in that the calcium compound is suspended or emul- sified in an oil phase.
Based on weight, the composition may thus comprise 0-80%, in particular 0-70% water phase, and 100-20%, in particu¬ lar 100-30% oil phase. The preferred mixing ratio is 40- 70% water phase and 60-30% oil phase.
The content of calcium calculated as free Ca in the fi¬ nished mixture is 1-25% by weight, preferably 10-20%.
It could not be expected in advance that it would be possible to formulate emulsions with such a high content of dissolved calcium compound in such a large amount of water phase, i.a. because of the increased density and increased ion strength of the water phase.
In the preferred embodiment, the calcium compound is thus dissolved in the aqueous phase in a water-in-oil emulsion. To ensure suitable emulsion stability, the emulsion con¬ tains one or more emulsifiers. Suitable emulsifiers are e.g. oil soluble non-ionic emulsifiers, in particular es¬ ters of polyvalent alcohols, preferably glycerol, with fatty acids or polymerized oils.
It has been found that a particularly good emulsion stabi- lity may be obtained with polyglycerol esters of polyme¬ rized soybean oil. The concrete emulsifier selection and emulsifier amount depend i.a. upon the ratio of water phase to oil phase, the type of the oil phase and the amount of dissolved cal¬ cium compound.
The most expedient emulsifier and emulsifier amount can thus be found by experiments.
The emulsifier is used in an amount of 0.5-10%, calculated on the finished mixture, in particular 1-4%, preferably 1.5-2.5%.
The composition of the invention may moreover contain additives such as mineral supplements, e.g. magnesium or selenium, vitamin D and flavouring substances, sweetening agents, antioxidants and preservatives. If desired, thickeners may moreover be added to one or both phases.
To produce the present composition in the form of an emul- sion, the calcium compound is dissolved in water together with optional preservatives and thickeners and is heated to about 50°C. This solution is mixed with an about 50°C hot solution of emulsifier and optional antioxidants, sweetening agents and flavouring substances in the oil used with vigorous stirring. The resulting emulsion may be homogenized if desired.
The suspension may be produced analogously, however with¬ out addition of water.
The desirable peroral dose is 50 g of free Ca which is administered in prophylactic treatment 24 hours before ex¬ pected calving, immediately after calving as well as 12 and 24 hours later. Peroral treatment is also used as a supplement to intra- veneous calcium treatment and is then dosed with 50 g of Ca 4, 12 and optionally 24 hours after the intraveneous treatment.
A composition according to the invention may e.g. be com¬ posed as follows:
CaCl2, Ph. Nord. 25%
Soybean oil 47%
Emulsifier 3%
Water 25%
Flavouring substances
(coconut and vanilla) 0.04%
Saccharine sodium 0.01%
Antioxidant
Preservative
A typical composition may consist of:
CaCl2, 6H20 300 g (corresponding to
50 g of Ca++
Water 100 g Emulsifier 16 g Soybean oil 380 g
Additives 4 g
800 g
The commercially available products "Calol®" and "KOVEL®" respectively contain - 8 -
CaCl2 2H20 200 g 200 g
Soybean oil 280 g 380 g
Water 200 g 200 g Auxiliary substances and flavour 20 g 20 g
700 g 800 g
The composition of the invention is being tested in a large number of herds.
Initial experiments have shown that the cows willingly take the composition. The composition has till now been tested as a supplement for intravenous administration of calcium borongluconate in confirmed milk fever incidences, where CaCl2 gel as well as placebo control were used for comparison. 8 g of Ca were administered intraveneously, as well as 8 g of Ca subcutaneously for precipitation in three groups of ten cows, where two groups were subse¬ quently treated with 50 g of Ca either as Calol®/ KOVEL® or as CaCl2 gel. The third group served as control.
Both oral treatments showed significant effects on the clinical symptoms. In terms of effect, there was no dif¬ ference between Calol®/KOVEL® and the gel, but Calol®/ KOVEL® was accepted much better by the cows and were much easier to administer. The test will be reported at the XVI World Buiatrics Congress, Bahia, Brazil, Wermuth et al. "New Treatment of Milkfever".
Jess Jørgensen et al., Dansk Vet. Tidsskrift, 1990, 73, 3 1/2, p. 140 refers to comparitive examinations between CaCl2 gels with hydroxyethylcellulose as gel former and a composition according to the invention in the form of an emulsion in 380 g of soybean oil. Both compositions con- tained 400 ml, 49% aqueous CaCl2, H20. It was conluded that the gel composition in the dose used can cause pronounced clinical and pathological side ef¬ fects, in particular by way of lesions of the stomach wall while the composition of the invention only involved rela- tively mild clinical symptoms and superficial or no patho¬ logical lesions.
In a further examination by the National Institut of Ani¬ mal Science, Ole Aaes "Report on the influence of various culture calcium compositions on feed intake when feeding according to appetite" it was demonstrated that, in addi¬ tion to the above-mentioned lesions on the stomach wall, the CaCl2 gels also reduced the appetite. Thus, feed in¬ take measured as kg dry matter was reduced by 2.8 feed units (FU), while Calol®/KOVEL® only reduced the feed in¬ take by 2.1 FU. However, to this should be added that about 3.2 FU were added with the soybean oil, which will give an unchanged or positive energy balance even with a digestibility of about 75%.

Claims

P a t e n t C l a i m s :
1. An orally administerable composition for prevention or treatment of calcium deficiency, e.g. milk fever in cattle, said composition containing as active ingredient a readily absorbable calcium compound, c h a r a c t e r ¬ i z e d in that the calcium compound is suspended or emulsified in an oil phase.
2. A composition according to claim 1, c h a r a c ¬ t e r i z e d in that the calcium compound is a water soluble calcium salt, preferably calcium chloride.
3. A composition according to claims 1-2, c h a r a c ¬ t e r i z e d in that the calcium compound is wholly or partially dissolved in the aqueous phase in a water-in-oil emulsion.
4. A composition according to claims 1-3, c h a r a c ¬ t e r i z e d in that the emulsion contains a water soluble, preferably non-ionic emulsifier in an amount of 0.5-10% by weight, preferably 1-4% by weight, in particu¬ lar 1.5-2.5% by weight, calculated on the total mixture.
5. A composition according to claim 4, c h a r a c ¬ t e r i z e d in that the emulsifier is an ester of a polyvalent alcohol, preferably glycerol, with fatty acids or with a polymerized oil.
6. A composition according to claim 5, c h a r a c ¬ t e r i z e d in that the emulsifier is a polyglycerol ester of polymerized soybean oil.
7. A composition according to any of the preceding claims, c h a r a c t e r i z e d in that the oil phase consists of one or more edible oils, preferably selected among soybean oil, rapeseed oil, groundnut oil and grape- seed oil.
8. A composition according to any of the preceding claims, c h a r a c t e r i z e d in that it consists of 0-80% by weight of water phase and 100-20% by weight of oil phase, preferably 40-70% by weight of water phase and 60-30% by weight of oil phase.
9. A composition according to any of the preceding claims, c h a r a c t e r i z e d in that the calcium content calculated as free Ca in the finished mixture 1-25% by weight, preferably 10-20% by weight.
10. A composition according to any of the preceding claims, c h a r a c t e r i z e d in that it further con¬ tains additivies selected among minerals, vitamin D, fla¬ vouring substances, sweetening agents, antioxidants and preservatives.
PCT/DK1990/000055 1989-02-27 1990-02-27 Orally administerable calcium supplement for cattle WO1990009797A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT90904254T ATE83664T1 (en) 1989-02-27 1990-02-27 ORAL CALCIUM SUPPLEMENT FOR LIVESTOCK.
US07/761,364 US5393535A (en) 1989-02-27 1990-02-27 Orally administerable calcium supplement for cattle
DE9090904254T DE69000663T2 (en) 1989-02-27 1990-02-27 ORAL AVAILABLE CALCIUM ADDITIVE FOR LIVESTOCK.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0926/89 1989-02-27
DK092689A DK159807C (en) 1989-02-27 1989-02-27 APPLICATION OF CALCIUM-SUSTAINABLE EMULSIONS FOR THE PREPARATION OF ORAL AGENTS FOR PREVENTION OR TREATMENT OF CALCIUM LACK OF Cattle, especially by calving fever

Publications (1)

Publication Number Publication Date
WO1990009797A1 true WO1990009797A1 (en) 1990-09-07

Family

ID=8099089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1990/000055 WO1990009797A1 (en) 1989-02-27 1990-02-27 Orally administerable calcium supplement for cattle

Country Status (9)

Country Link
US (1) US5393535A (en)
EP (1) EP0460080B1 (en)
JP (1) JP2784092B2 (en)
AT (1) ATE83664T1 (en)
AU (1) AU638001B2 (en)
DE (1) DE69000663T2 (en)
DK (2) DK159807C (en)
ES (1) ES2053183T3 (en)
WO (1) WO1990009797A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4402544A1 (en) * 1994-01-28 1995-08-03 Chevita Gmbh Use of calcium formate in orally administrable compositions
WO1998002143A1 (en) * 1996-07-16 1998-01-22 Jørgen Kruuse A/S An orally administrable, paste-like composition for veterinary use, a method for the preparation thereof, and the use of an oily vehicle for the manufacture of such composition
FR2760639A1 (en) * 1997-03-14 1998-09-18 Innothera Lab Sa MINERALO-VITAMIN THERAPEUTIC ASSOCIATION IN THE FORM OF A UNITABLE ORAL LIQUID PREPARATION
WO2002049657A1 (en) * 2000-12-21 2002-06-27 Massey University Methods and compositions for reducing or preventing onset of milk fever
EP2806871A4 (en) * 2012-01-26 2016-07-20 Univ Cincinnati Compositions and methods for improving lactation

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560920A (en) * 1995-04-07 1996-10-01 The United States Of America, As Represented By The Secretary Of Agriculture Calcium formulations for prevention of parturient hypocalcemia
US5962048A (en) * 1996-02-08 1999-10-05 Register; Jack W. Veterinary pharmaceutical method of administration
US5958464A (en) * 1996-02-08 1999-09-28 Register; Jack W. Veterinary pharmaceutical composition
AU7284198A (en) * 1997-05-06 1998-11-27 Stuhr Enterprises, Inc. Process for making an animal feed supplement
WO1999004648A1 (en) * 1997-07-25 1999-02-04 Board Of Regents For Oklahoma State University Methods for improving meat tenderness and related meat products and feedstuffs
SE512089C2 (en) * 1998-05-26 2000-01-24 Akzo Nobel Surface Chem Ways to prepare a malted dry feed with predetermined water content
US6262216B1 (en) 1998-10-13 2001-07-17 Affymetrix, Inc. Functionalized silicon compounds and methods for their synthesis and use
EP1162890B1 (en) * 1998-10-30 2005-10-12 RJ Innovation A method of preventing parturient hypocalcemia in animals and compositions used therein
US6355278B1 (en) 1999-03-31 2002-03-12 West Central Cooperative Dry dairy cow supplement
ES2269218T3 (en) * 1999-12-22 2007-04-01 Wisconsin Alumni Research Foundation CALCIUM FORMAT AS A FOOD SUPPLEMENT.
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
US20040202696A1 (en) * 2003-04-14 2004-10-14 Cts Chemical Industries Ltd. Administration form for veterinary use
JP4614202B2 (en) * 2004-08-04 2011-01-19 耕二 三津田 Milk fever preventive agent, milk fever preventive feed and milk fever preventing method
FR3025104B1 (en) * 2014-08-29 2017-11-24 Hy-Nutrition IMMEDIATE RELEASE BOLUS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE334766C (en) * 1919-09-28 1921-03-16 Hans Potratz Process for the production of strong calcium salt solutions in emulsion form
US2198165A (en) * 1936-04-28 1940-04-23 Hamburger Lodewijk Preparation containing calcium compounds
US3461203A (en) * 1964-12-28 1969-08-12 Leo Ab Method for preventing puerperal paresis
DE1792410A1 (en) * 1967-09-01 1971-11-11 Vitrum Apoteksvar Pharmacological composition and process for its preparation
US4259323A (en) * 1980-03-24 1981-03-31 Hoffmann-La Roche Inc. Potassium chloride emulsion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8401026A (en) * 1983-11-09 1985-06-03 Unilever Nv EDIBLE W / O / W EMULSION.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE334766C (en) * 1919-09-28 1921-03-16 Hans Potratz Process for the production of strong calcium salt solutions in emulsion form
US2198165A (en) * 1936-04-28 1940-04-23 Hamburger Lodewijk Preparation containing calcium compounds
US3461203A (en) * 1964-12-28 1969-08-12 Leo Ab Method for preventing puerperal paresis
DE1792410A1 (en) * 1967-09-01 1971-11-11 Vitrum Apoteksvar Pharmacological composition and process for its preparation
US4259323A (en) * 1980-03-24 1981-03-31 Hoffmann-La Roche Inc. Potassium chloride emulsion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dansk Veterinaertidsskrift, Vol. 73, No. 3, 1 February 1990 (Copenhagen) R.J. JORGENSEN et al.: "Calciumklorid til koer. Bivirkninger efter peroral indgivelse - En forelobig meddelelse", see pages 140-141. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4402544A1 (en) * 1994-01-28 1995-08-03 Chevita Gmbh Use of calcium formate in orally administrable compositions
EP0667152A1 (en) 1994-01-28 1995-08-16 Chevita GmbH Oral use of calcium formate for the treatment of calcium deficiency in animals
WO1998002143A1 (en) * 1996-07-16 1998-01-22 Jørgen Kruuse A/S An orally administrable, paste-like composition for veterinary use, a method for the preparation thereof, and the use of an oily vehicle for the manufacture of such composition
FR2760639A1 (en) * 1997-03-14 1998-09-18 Innothera Lab Sa MINERALO-VITAMIN THERAPEUTIC ASSOCIATION IN THE FORM OF A UNITABLE ORAL LIQUID PREPARATION
WO1998041217A1 (en) * 1997-03-14 1998-09-24 Laboratoire Innothera, Societe Anonyme Therapeutic combination of mineral and vitamin in units of liquid preparation for oral administration
WO2002049657A1 (en) * 2000-12-21 2002-06-27 Massey University Methods and compositions for reducing or preventing onset of milk fever
EP2806871A4 (en) * 2012-01-26 2016-07-20 Univ Cincinnati Compositions and methods for improving lactation

Also Published As

Publication number Publication date
US5393535A (en) 1995-02-28
DE69000663T2 (en) 1993-07-01
DK159807C (en) 1992-06-29
AU638001B2 (en) 1993-06-17
DK92689D0 (en) 1989-02-27
EP0460080A1 (en) 1991-12-11
DK159807B (en) 1990-12-10
DE69000663D1 (en) 1993-02-04
AU5183390A (en) 1990-09-26
EP0460080B1 (en) 1992-12-23
JP2784092B2 (en) 1998-08-06
DK92689A (en) 1990-08-28
JPH04503670A (en) 1992-07-02
DK0460080T3 (en) 1993-05-03
ES2053183T3 (en) 1994-07-16
ATE83664T1 (en) 1993-01-15

Similar Documents

Publication Publication Date Title
US5393535A (en) Orally administerable calcium supplement for cattle
CA2199398C (en) Composition for the treatment or prevention of an energy imbalance in ruminants
US3253988A (en) Antacid composition and method of using same
US6193986B1 (en) Oily composition with increased stability and process for producing the same
BR112013005915B1 (en) USE OF ABSCISIC ACID AND METHOD TO INCREASE THE NUMBER OF OFFSPRING PER LITTER
JPH05163160A (en) Nutrient preparation for prevention and treatment of infectious disease caused by immune depression
JP2000229832A (en) Skin lotion
JPS5948414A (en) Water-soluble preparation of vitamin e
JP3523260B2 (en) Fenbendazole formulation
US4496547A (en) Saccharide fatty acid ester for bloat-prevention or bloat-treatment
CN104997794A (en) Long-acting composite vitamin oral emulsion for livestock and preparation method thereof
EP0096728B1 (en) Prophylactic or therapeutic agent for bloat
FR2561522A1 (en) INJECTABLE SOLUTION, IN PARTICULAR FOR PROCESSING CETOSE AND PROCESS FOR PREPARING THE SAME
DE2640707B2 (en) Process for the production of medicinal preparations with a content of protein and peptide solutions which can be absorbed in the intestine
JPS62106018A (en) Water-based preparation containing vitamin e in high concentration
JP2906215B2 (en) High concentration calcium containing liquid
KR20220041147A (en) Compositions comprising simethicone and sucrose esters and their use as antifoams
JP3344833B2 (en) Mineral feed composition
WO2021255646A1 (en) A copper based composition for animal consumption
JPH0214326B2 (en)
JPH0352817A (en) Therapy for animal
BR112014022286B1 (en) animal feed composition containing encapsulated delta-lactone gluconoid
JP3198270B2 (en) Feed and its manufacturing method
JPS63133962A (en) Auxiliary nourishing food
CA2543505A1 (en) Animal husbandry method for administering a vitamin e derivative and formulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990904254

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990904254

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990904254

Country of ref document: EP